Two 12-week phase 3 trials and a 43-week extension will test 8 mg and 16 mg HLP003 added to antidepressants, with APPROACH enrollment now complete.
|Articles|September 16, 2008
- April15 2003
- Volume 10
- Issue 7
PHARMACEUTICAL STOCKWATCH
Advertisement
Articles in this issue
about 18 years ago
Secure Tomorrow, Don't Lose Todayabout 18 years ago
Avoid the Turmoil of Insurance Mistakesabout 18 years ago
Bulletproof Your Car from the IRS' Aimabout 18 years ago
The PMD Answerman Q & Aabout 18 years ago
Impart Financial Values to Your Childrenabout 18 years ago
Watch Your Nest Egg's Financial Healthabout 18 years ago
Invest Some Land in Your 401(k) Accountabout 18 years ago
Plan According to Social Security Rulesabout 18 years ago
Discover Another Defined-Benefit Avenueabout 18 years ago
Know All Your Estate Planning BenefitsAdvertisement
Related to this article
This preview of EADV 2026 provides a teaser of new data and interviews being highlighted at this Vienna dermatology conference.
Phase 2b AMPLIFIED data show a 42.7% UACR drop in AMKD with modest proteinuria; AMPLITUDE interim data are due early 2027.
Agusti, chair of the GOLD Board of Directors, discusses which COPD diagnostic bottleneck AI is closest to solving and more.
George Vasquez-Rios, MD, explains how the ASN's GD-C Compendium curates glomerular disease guidance for general clinicians and specialists alike.
Andrew Cutler, MD, says real-world MDD patients respond to adjunctive cariprazine like trial participants, with gains in mood and function within weeks.
Frances Lee, MD, on the stigma driving under-detection of ALD and its disproportionate rise in women and younger adults.
SOCS leaders explain SOCS Serves, a toolkit-based program connecting dermatology volunteers with students and underserved communities.
Advertisement
Advertisement
Trending on HCPLive
1
ProACt Data Show Early Functional Gains with Adjunctive Cariprazine In MDD
2
Half-Life vs. Real Life: How Real-World Evidence Is Reframing Wet AMD Treatment
3
How the ASN's GD-C Compendium Aims to Unify Glomerular Disease Care
4
DAPA-TRIO-HF: Dapagliflozin Improves HF Outcomes Regardless of Healthcare Setting
5